2014 – Virobay to present data on two Cathepsin S inhibitor programs in neuropathic pain and Alzheimer's disease at the 2014 Society for Neuroscience Annual Meeting more
2014 – Virobay completes $8 million Series B preferred stock financing more
2014 – Virobay appoints Thomas J. Dietz, Ph.D. to the Virobay Board of Directors more
Robert F. Booth, Ph.D. has served as our Chief Executive Officer, President, Secretary and a member of our board of directors since May 2010 and he was previously our Executive Chairman and a member of our board of directors from July 2006 to May 2010. From July 2006 to May 2010, Dr. Booth served as an Operating Partner and Senior Advisor at TPG Biotechnology Partners, LP, a venture capital company. From December 2006 to July 2007, Dr. Booth served as the acting Chief Scientific Officer of Galleon Pharmaceuticals, Inc., a company which is developing new therapeutics for diseases of the respiratory system. From 2002 to 2006, Dr. Booth was the Chief Scientific Officer at Celera Genomics Corporation, or Celera, a drug discovery and development company. Dr. Booth served as Senior Vice President at Roche Bioscience, a part of F. Hoffmann-La Roche Ltd, or Roche, from 1996 to 2002, where he was responsible for research and early development activities in the therapeutic areas of inflammation, autoimmunity, respiratory diseases, transplantation, bone diseases and viral diseases. Dr. Booth was a member of the Global Research Management Team and a member of the Business Development Committee, which oversaw licensing opportunities for Roche. From 1989 to December 1995, Dr. Booth served as Director of Biology for Roche Products Ltd, a part of Roche’s research operation, which was located in the United Kingdom. Dr. Booth currently serves on the boards of directors of Pharmacyclics, Inc., Galleon Pharmaceuticals, Inc. and Glialogix, Inc., and is Chairman of the Scientific Advisory Board at Galleon Pharmaceuticals, Inc. Dr. Booth also serves as a member of the Scientific Advisory Boards of ShangPharma Corporation, Elcelyx Therapeutics, Inc. and NaZura Biohealth, Inc. Dr. Booth received a B.Sc. and a Ph.D. from the University of London in biochemistry.
Jeffrey W. Bird, M.D., Ph.D. has served on our board of directors since August 2006. Dr. Bird has been a Managing Director of Sutter Hill Ventures, a venture capital firm based in Palo Alto, California, since 2002. Dr. Bird currently serves on the boards of directors of Portola Pharmaceuticals, Inc., Threshold Pharmaceuticals, Inc., and a number of private biotechnology companies. For more than ten years Dr. Bird was an executive at Gilead Sciences, Inc., serving most recently as SVP of Business Operations with responsibility for Commercial Groups and Corporate Development. Dr. Bird received a B.S. in Biological Sciences from Stanford University, a Ph.D. in Cancer Biology and an M.D. from Stanford Medical School.
Thomas J. Dietz, Ph.D. has served on our board of directors since February 2014. Dr. Dietz has served as Chairman and Chief Executive Officer of Waypoint Holdings, LLC, a financial services firm, since December 2010. From January 2009 to November 2010, Dr. Dietz served as head of the investment banking division at Wedbush Securities Inc., or Wedbush, a financial services firm. From 2004 to January 2009, Dr. Dietz served as Co-Chief Executive Officer and then Chief Executive Officer and a director of Pacific Growth Equities, LLC, an investment bank and institutional brokerage firm, which in January 2009 was acquired by Wedbush. Dr. Dietz currently serves as the Chairman of Galleon Pharmaceuticals, Inc., and on the boards of directors of Glialogix, Inc. and Transcept Pharmaceuticals, Inc. Dr. Dietz received a B.S. in Biology from the State University of New York, Albany and a Ph.D. in molecular biology and biochemistry from Washington University in St. Louis.
Daniel S. Janney has served on our board of directors since June 2006. Mr. Janney has been a managing director at Alta Partners Management Corporation, a life sciences venture capital firm, or Alta, since 1996. From 1993 to 1996, Mr. Janney served as Vice President in the biotechnology investment banking group at Montgomery Securities, which was acquired by NationsBank Corp. in June 1997. Mr. Janney currently serves on the boards of directors of Alba Therapeutics Corporation, DiscoveRx Corporation, Lithera, Inc., Prolacta Bioscience, Inc. and Esperion Therapeutics, Inc. Mr. Janney served on the boards of directors of Chemgenex Pharmaceuticals Limited and Anesiva, Inc. from 2007 to 2011 and 2008 to 2010, respectively. Mr. Janney received a B.A. in history from Georgetown University and an M.B.A. from the Anderson School at University of California, Los Angeles.
Heather Preston, M.D. has served on our board of directors since August 2006. Since 2005, Dr. Preston has served as a Partner and Managing Director at TPG BioTechnology Partners, LP, a biotechnology venture capital firm. From 2002 to 2005, Dr. Preston served as a medical device and biotechnology venture capital investor at J.P. Morgan Partners, LLC, a private equity firm, and New Enterprise Associates, a venture capital firm. From 1997 to 2002, Dr. Preston served as a leader of the pharmaceutical and medical products consulting practice at McKinsey & Co., Inc. in New York. Dr. Preston currently serves on the boards of directors of Alder BioPharmaceuticals, Inc. and numerous private companies. Dr. Preston received a B.S. in biochemistry from the University of London and an M.D. from Oxford University.